Bone mineral density and the risk of kidney disease in patients with type 1 diabetes

Sabina Chaudhary Hauge*, Henrik Øder Hjortkjær, Frederik Persson, Simone Theilade, Morten Frost, Niklas Rye Jørgensen, Peter Rossing, Ditte Hansen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Aim: To explore the association between bone disorder and the risk for progression of diabetic kidney disease (DKD) in persons with type 1 diabetes mellitus (T1DM). Methods: In this prospective cohort study the association between bone mineral density (BMD), bone-derived factors (sclerostin, Dickkopf-1, and osteoprotegerin (OPG)), and four outcomes were investigated: 1) progression of albuminuria; 2) decline in estimated glomerular filtration rate (eGFR) ≥30 %; 3) kidney failure (KF); and 4) a composite kidney outcome consisting of at least one of the outcomes. Results: In 318 participants (median follow-up time 5.5 years) patients with osteoporosis (BMD with T-score < −2.5) had increased risk of eGFR decline: hazard ratio (HR) 2.56 (95 % CI 1.06–6.19, p = 0.04), KF: HR 9.92 (95 % CI 1.16–84.95, p = 0.04), and the composite kidney outcome: HR 2.42 (95 % CI 1.18–4.96, p = 0.02). Patients with high OPG had increased risk of eGFR decline, KF, and the composite outcome, compared to patients with low OPG in unadjusted analysis. No bone-derived factor was associated with any outcome in adjusted analyses. Conclusions: In patients with T1DM low BMD was associated with progression of DKD, suggesting an interaction between bone and kidney.

Original languageEnglish
Article number108927
JournalJournal of Diabetes and its Complications
Volume39
Issue number2
Number of pages7
ISSN1056-8727
DOIs
Publication statusPublished - 2025

Bibliographical note

Publisher Copyright:
© 2024 The Authors

Keywords

  • Bone mineral density
  • Chronic kidney disease
  • Dickkopf-1
  • Osteoprotegerin
  • Sclerostin
  • Type 1 diabetes

Cite this